Ekkio backs Mediliant

Mediliant represents the fourth investment completed via Ekkio Capital IV, which closed on €161m in May 2018. The investment is the GP's first transaction in Switzerland and second abroad, after the backing of Germany-based GAB consulting in 2016, Unquote understands.

The fund focuses on lower-mid-market companies, investing between €5-25m in deals with an enterprise value of between €15-50m.

The GP is planning to foster Mediliant's buy-and-build strategy and expansion into the US market.  

The company was orginally founded by Johnson&Johnson in 1999. It was subsequently sold to medical devices company Biomet in 2012; a year later management bought the business back.

Company
Founded in 2013 and based in Le Locle, Mediliant is a contract manufacturing company in the medical devices industry. The business manufactures medical devices, from raw material to sterile packaged products. The devices are used in the medical fields of trauma, spine, orthopaedics and dentistry.

People
Ekkio Capital – Jean-Marc Scéo (president).
Mediliant – Denis Leissing (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Switzerland
• Ekkio Capital